Paving New Ways for Drug Discovery & Development: Targeted Protein Degradation

The Dana-Farber Targeted Protein Degradation Webinar Series discusses new discoveries and modalities in protein degradation.

In this webinar, Senior Research Scientist, Dr. Danette Daniels, focuses primarily on proteolysis-targeting chimeras, or PROTACs. A variety of topics are covered including the design, potency, and efficacy of PROTACs in targeted protein degradation. Watch the video below to learn more about how PROTACs are shifting perspectives through fascinating research and discoveries in targeted protein degradation.

Learn more about targeted protein degradation and PROTACS here.

GPCR Targets are a Dimer a Dozen

G protein-coupled receptors (GPCRs) are the most prevalent gene family in the human genome. They are involved with everything from our sense of smell to immune system function to tumor growth. Unsurprisingly, GPCRs have been a hotbed for research and development. Of the 7,038 approved drugs analyzed for this blog post, I found that 29% of them target Class A (Rhodopsin-like) GPCRs, and 35% target any GPCR. In the spirit of Internet pop culture, I made a “quiz” to see if you can guess the top 10 receptors by their ligand’s chemical structure.

Can you guess these GPCR receptors by their ligand chemical structures?

Continue reading “GPCR Targets are a Dimer a Dozen”